

Ocular Diseases Forum 3

Wednesday, May 28, 2025
University of California, Washington Center
1608 Rhode Island Avenue NW, Washington DC 20036

AGENDA

8:00 AM	Registration & Breakfast	
9:00 AM	Session I: Introductions & Project Overview	
9:00 AM	Moderator: Veronica Miller, Forum	
9:00 AM	Welcome & Introductions	<i>Daniel Chung, SparingVision Veronica Miller, Forum José-Alain Sahel, UPMC Vision Institute</i>
9:05 AM	Governance & Forum Process	<i>Alessi Ayvaz & Sehyr Khan, Forum</i>
9:10 AM	Objectives for Ocular Diseases Forum 3 (ODF3)	<i>Claire Gelfman, Forum</i>
9:15 AM	Session II: Ongoing Collaborations and Current Efforts	
9:15 AM	Moderators: Daniel Chung, SparingVision & José-Alain Sahel, UPMC Vision Institute	
9:15 AM	Ongoing Efforts: ERN-EYE	<i>Bart Leroy, Ghent University</i>
9:30 AM	Regulatory Endpoints and Trial Design for IRDs (REDI) Working Group: Ongoing Efforts	<i>Rachel Huckfeldt, Massachusetts Eye and Ear</i>
9:45 AM	Discussion	<i>All participants</i>
10:00 AM	Session III: Full-field Stimulus Testing (FST) for Consideration as an Endpoint	
10:00 AM	Moderators: Ash Jayagopal, Opus Genetics & Bart Leroy, Ghent University	
10:00 AM	Overview: Endpoints Working Group	<i>Sehyr Khan, Forum</i>
10:15 AM	Overview of Full-field Stimulus Testing (FST)	<i>Artur Cideciyan, University of Pennsylvania*</i>
10:45 AM	FST Q&A	<i>All participants</i>
11:15 AM	Break	
11:45 AM	Session III: Full-field Stimulus Testing (FST) for Consideration as an Endpoint (Continued)	
11:45 AM	Moderators: Ash Jayagopal, Opus Genetics & Bart Leroy, Ghent University	
11:45 AM	Clinical Trial Data Presentation #1 (Spark)	<i>Daniel Chung, SparingVision</i>
12:00 PM	Full-field Stimulus Test (FST) as a Clinical Endpoints in a Phase 1/2 Study of ATSN-101	<i>Laura Pardon, Atsena Therapeutics</i>
12:15 PM	Recovery of Cone-Mediated Vision in a Severe Ciliopathy after Gene Augmentation: One Year Results of a Phase Ib/Ila Trial for LCA5-LCA	<i>Tomas Aleman, University of Pennsylvania*</i>
12:30 PM	FST Minimal Clinically Important Difference	<i>Lee McDaniel, Jaeb Center for Health Research</i>
12:45 PM	Open Discussion	<i>All speakers</i>
1:15 PM	Lunch	
2:15 PM	Session IV: Endpoints Working Group: Defining the Patient Population for FST	
2:15 PM	Moderators: Daniel Chung, SparingVision & José-Alain Sahel, UPMC Vision Institute	
2:15 PM	Considerations for Clinical Trial Population for FST	<i>Rachel Huckfeldt, Massachusetts Eye and Ear David Bingaman, MERIT CRO* David Hoelscher, Fortrea* Tanya Richardson, Fortrea* David Tanzer, Lexitas</i>
2:30 PM	Panel Discussion: How does FST impact clinical trial inclusion criteria?	
2:45 PM	Session V: Endpoints Working Group: Looking Towards the Future	
2:45 PM	Moderators: Zuhair Butuner, Sepul Bio & Claire Gelfman, Forum	
2:45 PM	Patient Perspective: Fireside Chat	<i>Matthew Baier Ned Reade, BCM Families Foundation Barbara Wade Sergent, BCM Families Foundation</i>
3:00 PM	Outcome measures in IRDs: Focus on PBTs	<i>José-Alain Sahel, UPMC Vision Institute</i>
3:15 PM	Patient-Reported Outcome Measures in IRDs: Informing a Consensus Statement	<i>Todd Durham, Foundation Fighting Blindness</i>
3:30 PM	Open Discussion	<i>All participants</i>
4:00 PM	Break	
4:30 PM	Session VI: Endpoints Working Group: Considerations for Age-Related Macular Degeneration (AMD)	
4:30 PM	Moderator: Maryam Mokhtarzadeh, Regenxbio & Cheryl Rowe-Rendleman, Omar Consultants	
4:45 PM	Current Landscape for iAMD Drug Development	<i>Cheryl Rowe-Rendleman, Omar Consultants</i>
5:00 PM	Discussion	<i>All participants</i>
5:30 PM	Session VII: Wrap Up & Next Steps	
5:30 PM	Closing Panel	<i>Daniel Chung, SparingVision Veronica Miller, Forum José-Alain Sahel, UPMC Vision Institute</i>
5:45 PM	Summary & Next Steps	<i>All participants</i>
5:45 PM	Adjourn and Evening Reception	
7:15 PM	Reception End	

*indicates remote participation